Form 4: Intra-Cellular Therapies Executive Mark Neumann Reports Stock Transactions

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Summary

• On March 1, 2025, Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, reported transactions involving common stock and restricted stock units.
• Neumann exercised 8,742 restricted stock units, which converted into an equal number of common stock shares.
• 44,730 shares were disposed of.
• 3,709 shares were withheld by the issuer to cover tax obligations at a price of $128.2 per share.
• Following these transactions, Neumann directly owns 41,021 shares of Intra-Cellular Therapies common stock and 17,485 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider activity and can be scrutinized by investors for signals about the company's prospects.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect the normal course of executive compensation.
• Employees holding similar stock units may experience similar transactions.

Key Dates